Clinical Overview: Issues in Kaposi’s

Four questions are posed that are critical to the development of improved therapeutic and prophylactic strategies for Ka-posi’s sarcoma (KS). 1) Can we predict who will develop KS? Accurate identification of high-risk factors for KS develop-ment is essential for the development of KS prophylaxis tri-als. 2) Can developing insights into KS pathogenesis be translated into improved therapeutic and/or new prophylac-tic strategies for patients at high risk? Several approaches are being developed that target new blood vessel develop-ment, inflammatory cytokines, and the viruses that are im-plicated in KS pathogenesis. 3) How does the improved prog-nosis for human immunodeficiency virus (HIV)-infected patients affect KS treatment strategy? Improved anti-HIV therapy has implications for the timing of KS therapy, the choice of therapeutic approaches, and the potential for ad